Effect of Addition Oral Montelukast to Standard Treatment in Acute Asthma in Hospitalized Preschool Children
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Leukotriene receptor antagonists (LTRAs) are well established in the management of outpatient
asthma. Montelukast is a potent, specific, orally active, cysteinyl leukotriene receptor
antagonist with a rapid onset of action.However, there is very little information as to their
role in acute asthma exacerbations.
The purpose of this study is to determine if adding oral montelukast to the maximal standard
treatment in children hospitalized for acute asthma has any additive benefit.